4. Flamel Technologies ( FLML) is a biopharmaceutical company with two intellectual property platforms: Medusa, for the controlled release of proteins, peptides and other molecules; and Micropump, for the controlled release of drugs best absorbed in the small intestine. Boosted by license and research revenue and higher Coreg CR (Carvedilol Phosphate Extended-Release) royalties, Flamel reported revenue of $6.8 million for the first quarter of 2011 versus $8.1 million in the year-ago period. Commenting on the results, Stephen H. Willard, Flamel's CEO, said in a press statement, "Our revenues in the first quarter were lower than expected, as we were able to sign license agreements in April 2011, rather than in the first quarter." The company has signed more than twenty-five agreements including nine of the largest pharmaceutical companies in the world for the joint development of promising molecules. Analysts expect the stock to gain around 107% over the next one year.
The ex-dividend date for Telecom Corporation of New Zealand (NYSE:NZT) is tomorrow, March 20, 2012. Owners of shares as of market close today will be eligible for a dividend of 37 cents per share. At a price of $10.19 as of 9:30 a.m., the dividend yield is 6.6%.
The ex-dividend date for Telecom Corporation of New Zealand (NYSE:NZT) is tomorrow, August 30, 2011. Owners of shares as of market close today will be eligible for a dividend of 39 cents per share. At a price of $11.58 as of 9:30 a.m., the dividend yield is 5.1%.